



58th PSA Annual Convention “Beyond the Operating Room: Innovation, Safety, Excellence” Research Forum 2026

Mechanics and Instructions for Submission

I. INTRODUCTION

This is a scientific research forum designed to promote, stimulate, and encourage ALL Anesthesiologists to write, present, and publish original research, including systematic reviews/meta-analyses and case reports relevant to the current practice of Anesthesiology in our country.

The 2026 Research Forum will comprise an Exhibit Hall Poster Presentation featured throughout the 3-day Annual Convention, as well as Oral Presentations in separate Moderated Sessions for the Residents’ Research and the Fellows’ Research. For the Poster Presentation, entries will be categorized into one of the following: 1) Fellow’s Research, 2) Residents’ Research, and 3) non-competition submissions.

II. OBJECTIVES

1. To promote, stimulate, and encourage scholarly work, particularly the conduct, presentation, and eventual publishing of original research and case reports among Filipino anesthesiologists.
2. To provide an avenue for anesthesia residents in training, residents and fellows alike, to exhibit scholarly data confidently and convincingly through hard evidence in both poster and oral presentation formats.
3. To foster camaraderie among researchers and like-minded colleagues of the Society who will attend, discuss, and network during the Research Forum.

III. RULES AND REGULATIONS

1. Who can submit abstracts?
 - a. The Research Forum is open to all Residents and Fellows-in-Training of the PSA in Good Standing who plan to register and attend the 58th Annual Convention on site.
 - b. Competition categories are open for:
 - i. Residents in training or have graduated within one year of the PSA Annual with original research.
 - ii. Fellows in training with original research or case reports.
 - c. Non-competition poster presentations are open for:
 - i. Trainees with **unpublished** work who have presented in other research fora (provided there is no conflict with the previous submission)

2. Criteria for Eligibility

- a. The primary author (i.e., the individual submitting the abstract and presenting at the conference) was involved throughout the completion of the research work.
 - i. Authors submitting their abstracts for the competition categories should be current trainees or within one (1) year of graduation from their Fellowship/Residency training.
 - ii. Presenters should be registered to attend the PSA Annual Convention by **November 13, 2026**.
- b. Completed papers and works still for finalization of their manuscripts are eligible for participation, provided the data collection and analysis are final. Revision of the submitted results in the abstracts, including the table or figure, will NOT be allowed. You may supplement your results with new data obtained since abstract submission, but the original data should remain in the poster/oral presentation. Qualified abstracts for the oral presentation will be given an additional month from notification to complete the paper's final manuscript.
 - i. The submitted research abstract must not have been published in any local or international peer-reviewed journal as a full manuscript by **November 13, 2026**. Please give us the courtesy of notification if your work will be accepted for publication after the submission deadline.
 - ii. Abstracts describing human subject research **must** receive Institutional Review Board or Ethics Review Committee approval before the submission deadline.
 - iii. The primary responsibility for compliance with any disclosure or nondisclosure requirements resides solely with the researchers.
 - iv. There is NO LIMIT to the number of abstracts an author may submit.
 - v. For multiple authors, only one author (e.g., primary author) per abstract could be an active participant. The active participant will receive an individual certificate with their name and the title of the abstract written on it. It is his or her responsibility to obtain permission from all other authors, including consultant advisers/supervisors.
- c. Moderated Session Oral Presentation
 - i. Authors of papers selected by the Abstracts Committee for oral presentation need to be able to submit a full and completed manuscript of their research paper by **October 30, 2026**. If the author/s cannot realistically meet the deadline, please let us know early on so we can give another Resident/Fellow the opportunity to present.
 - ii. In case an author submits multiple abstracts and has more than one paper qualifying for the oral presentation, he/she should assign a co-author to present the other research.

3. Rules of Judging and Related Incentives
 - a. Abstracts are peer-reviewed according to the following criteria: originality/good design, scientific impact/careful analysis, quality/clear writing, and overall abstract quality.
 - b. The abstract review process is anonymous. A minimum passing score will be required to present at the PSA Research Forum 2024.
 - c. All abstract submissions will be reviewed and screened by our Abstracts Committee. They will decide on the Top 10 Abstracts (Residents' Research)/Top 7 (Fellows' Research) for Oral Presentation and who will qualify for the Exhibit Hall Poster Presentation.
 - d. You will be notified by email by **September 15, 2026**, indicating if you are accepted and to what category and format you have been invited for (Poster or Oral). It is the responsibility of the primary author to share the notifications with their co-authors.
 - e. During the oral presentation, a distinguished panel of Judges who have no conflict of interest with any of the research to be presented will choose the winners.
 - f. Decisions of the Abstract Committee and the Panel of Judges are final.
 - g. All **abstracts** will be published as submitted as a supplementary issue of the Philippine Journal of Anesthesiology and will be asked for a waiver by the editorial team of the PJA. Author/s who wish not to have their work included in the issue should indicate in the waiver that they will NOT consent to publication. This only applies to the abstract. For publication of the entire manuscript, the author/s will have to undergo the standard submission and peer-review process of the PJA.

IV. INSTRUCTIONS FOR ABSTRACT SUBMISSION

1. All abstract submissions should be emailed to psaresearchforum@gmail.com with the subject heading: "PSA Research Forum 2026 Abstract Submission" and specify if a) Fellow/Resident Research.
 - a. Indicate in the email the name of the primary author, all the other authors, the institution/s of affiliation, and the title of the research abstract.
 - b. The attachments should include: 1) the Portable Document Format (PDF) copy of an anonymized, computer-written research abstract using 11-point Arial font, double spaced, A4 sized, and with 1" margin on all borders; 2) the IRB/ERC approval if the research involves human participants; 3) Disclosure of Conflict of Interest, if applicable. 4) Printout of TURNITIN Results indicating < 20% plagiarism.

2. Format for Submission of Abstract

- a. Abstracts should contain:
 - i. **Title:** The title must be brief and accurately reflect the content of the Abstract and must be typed in boldface type and in title case.
 - ii. **Introduction:** State the hypothesis or objective of the research in a simple manner; questions should be concrete and testable. Provide brief background and context of the work enough to establish the importance of or need for the research (e.g., generate new knowledge, answer whether a previous observation can be replicated, document if previous findings can be applied to a different population, or determine if improved measurement techniques can clarify a relationship, etc.)
 - iii. **Methods:** Describe the study design and the stepwise approach to what was done. Identify the research participants, primary and secondary measurements and outcomes, and the existing instruments or procedures. State how internal and external validity was maximized and bias/error minimized. Comment with approval from the appropriate animal or human ethical review Board should be stated if applicable.
 - i. For case reports, the **Description of the Case** replaces the Methods section.
 - iv. **Results:** Use design-appropriate raw data to characterize the primary and secondary outcomes and include design-appropriate inferential or descriptive statistical indices. Tabulated or graphical representation of the result is encouraged. However, only one table or figure can be included per abstract and must be incorporated in the PDF submitted. The image must have a resolution of at least 300x300 pixels per inch. Ensure that the data is legible. Submission of abstracts without data is not acceptable.
 - i. For case reports, a short **Discussion** replaces the Results section.
 - v. **Conclusion:** State a relevant and succinct summary that addresses the original research question or hypothesis. The results must support it; it should not extrapolate beyond the results of the study, not repeat the results, and not introduce findings not presented in the results section. Avoid interpretations, explanations, and speculations.
 - vi. **Reference(s):** Not more than 3-5 references are necessary. Use the Vancouver Citation Style.
 - vii. **Keywords:** Include two to three keywords that describe the research question.
- b. Authors may follow appropriate EQUATOR (Enhancing the QUALity and Transparency Of health Research) guidelines for reporting found in (<https://www.equator-network.org/>) to help with the preparation of the abstract.
- c. The identity of the author/s, their institution, or any identifying data should NOT BE MENTIONED anywhere in the title or body of the abstract.
- d. The main body of the abstract should **not exceed 600 words** and must be written in correct English (i.e., professional language and style free of grammatical or technical errors).
- e. Jargon and undefined abbreviations should be avoided. All drugs are to be identified consistently in the abstract by generic names. Have an experienced colleague/mentor proofread and critique the abstract prior to submission.

3. IRB/ERC approval documentation **must** be attached to the abstract submission.
4. Upon successful submission, authors will receive an acknowledgment via email within one week. Lack of acknowledgment will indicate that the abstract was not received. Please get in touch with the PSA Secretariat for confirmation or any questions.
5. Abstracts must be received by:
 - a. First closing date: **August 20, 2026**.
 - b. Abstracts received after this date will not be accepted.
 - c. Upon notification of acceptance of the abstract (by September 15, 2026), the presenting author must register for the Annual Convention before **November 15, 2026**. Unfortunately, we cannot provide complimentary registration for this year's forum.
6. Plagiarism will be checked and will not be tolerated. Submitted works found plagiarized can and will be removed from the list of presenters even after the notification has been sent.
7. Once an abstract has been submitted, no further changes can be made to the results section, including the table or figure, as previously mentioned.

V. INSTRUCTIONS FOR FULL MANUSCRIPT SUBMISSION (ORAL PRESENTATION ONLY) AND CONDUCT OF THE EXHIBIT HALL POSTER PRESENTATION AND THE MODERATED ORAL PRESENTATION

1. Final instructions and complete mechanics will be sent to qualified authors/presenters during the notification deadline on **October 16, 2026**.